These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35537933)

  • 21. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the use of methotrexate in psoriatic arthritis.
    Cañete JD; Ariza-Ariza R; Bustabad S; Delgado C; Fernández-Carballido C; García Llorente JF; Loza E; Montilla C; Naranjo A; Pinto JA; Queiro R; Ramírez J; Tornero-Molina J
    Reumatol Clin (Engl Ed); 2018; 14(4):183-190. PubMed ID: 29050840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
    Torre Alonso JC; Díaz Del Campo Fontecha P; Almodóvar R; Cañete JD; Montilla Morales C; Moreno M; Plasencia-Rodríguez C; Ramírez García J; Queiro R
    Reumatol Clin (Engl Ed); 2018; 14(5):254-268. PubMed ID: 29111261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).
    Qu X; Zhang S; Tao L; Song Y
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):799-805. PubMed ID: 26918950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis.
    Laires PA; Carrilho M; Tavares-Costa J; Lucas P; Machado P; Cunha-Miranda L; Pimentel-Santos F; Santos H; Vieira-Sousa E; Santos MJ
    Acta Reumatol Port; 2020; 45(1):46-57. PubMed ID: 32578579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates.
    Alnaqbi KA; Hannawi S; Namas R; Alshehhi W; Badsha H; Al-Saleh J
    Int J Rheum Dis; 2022 Oct; 25(10):1107-1122. PubMed ID: 35916205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.
    Richard MA; Barnetche T; Rouzaud M; Sevrain M; Villani AP; Aractingi S; Aubin F; Beylot-Barry M; Joly P; Jullien D; Le Maître M; Misery L; Ortonne JP; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2014 Aug; 28 Suppl 5():3-12. PubMed ID: 24985557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations.
    Balato A; Campione E; Cirillo T; Malara G; Trifirò C; Bianchi L; Fabbrocini G
    Dermatol Ther; 2020 May; 33(3):e13440. PubMed ID: 32306448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Points to Consider in the Foundation of Multidisciplinary Units for Psoriatic Arthritis: A Delphi Study and a Systematic Review of the Literature.
    Gratacos-Masmitja J; Luelmo-Aguilar J; Zarco-Montejo P; Botella-Estrada R; Carrizosa-Esquivel AM; Garcia-Vivar ML; Perez-Barrio S; Roman-Ivorra JA; Ruiz-Montesino MD; Lopez-Estebaranz JL
    Adv Ther; 2017 Jan; 33(12):2150-2159. PubMed ID: 27757814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.
    Lo Gullo A; Becciolini A; Parisi S; Del Medico P; Farina A; Visalli E; Dal Bosco Y; Molica Colella AB; Lumetti F; Caccavale R; Scolieri P; Andracco R; Girelli F; Bravi E; Colina M; Volpe A; Ianniello A; Ditto MC; Nucera V; Franchina V; Platé I; Di Donato E; Amato G; Salvarani C; Bernardi S; Lucchini G; De Lucia F; Molica Colella F; Santilli D; Mansueto N; Ferrero G; Marchetta A; Arrigoni E; Foti R; Sandri G; Bruzzese V; Paroli M; Fusaro E; Ariani A
    J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG; Lee YH
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.